中华医学杂志
中華醫學雜誌
중화의학잡지
National Medical Journal of China
2015年
23期
1815-1818
,共4页
绝经激素治疗%雌二醇屈螺酮%替勃龙%动脉粥样硬化性心血管疾病
絕經激素治療%雌二醇屈螺酮%替勃龍%動脈粥樣硬化性心血管疾病
절경격소치료%자이순굴라동%체발룡%동맥죽양경화성심혈관질병
Postmenopausal hormone replacement therapy%Estradiol-drospirenone combination%Tibolone%Carotid atherosclerotic disease
目的 探讨新型连续联合复方制剂安今益(雌二醇屈螺酮片)治疗女性绝经后症状的临床疗效、安全性和对血脂代谢影响.方法 采用配对对照回顾性临床研究,对2012年1月至2014年10月北京朝阳医院妇科门诊就诊接受安今益(1 mg 17β-雌二醇和2 mg屈螺酮/片,隔日1片)治疗绝经症状女性27例,和同时期同年龄段接受利维爱(tibolone 2.5 mg/片,隔日1片)治疗26例对照,收集临床资料,服药前、服药12周和停药2个月血清激素、血脂、空腹血糖水平,以及盆腔、乳腺和颈动脉血管超声数据.结果 两组对象年龄、绝经时间、体质量指数和临床患病情况具有可比性.服药前安今益组E2水平(12±10) ng/L,甘油三酯(TG) (2.0±1.1) mmol/L,脂蛋白a(LPa) (47±43) mmol/L;利维爱组E2水平(23 ±12) ng/L,TG(1.3±0.7)mmol/L,LPa(28±14) mmol/L.服药12周后安今益组E2水平(30 ±18) ng/L,TG (1.6±1.1) mmol/L,LPa(37±36) mmol/L;利维爱组E2水平(23 ±9) ng/L,TG(1.1±0.6) mmol/L,LPa(18±12) mmol/L.安今益组服药后子宫内膜厚度增加,23例服药中发生阴道出血.结论 安今益作为绝经后女性MHT连续联合治疗新型药物,能很好缓解绝经后相关症状,调节血脂代谢和保护心血管系统作用强于利维爱,阴道出血发生率高、子宫内膜增厚和乳腺胀痛不适降低了使用者依从性.
目的 探討新型連續聯閤複方製劑安今益(雌二醇屈螺酮片)治療女性絕經後癥狀的臨床療效、安全性和對血脂代謝影響.方法 採用配對對照迴顧性臨床研究,對2012年1月至2014年10月北京朝暘醫院婦科門診就診接受安今益(1 mg 17β-雌二醇和2 mg屈螺酮/片,隔日1片)治療絕經癥狀女性27例,和同時期同年齡段接受利維愛(tibolone 2.5 mg/片,隔日1片)治療26例對照,收集臨床資料,服藥前、服藥12週和停藥2箇月血清激素、血脂、空腹血糖水平,以及盆腔、乳腺和頸動脈血管超聲數據.結果 兩組對象年齡、絕經時間、體質量指數和臨床患病情況具有可比性.服藥前安今益組E2水平(12±10) ng/L,甘油三酯(TG) (2.0±1.1) mmol/L,脂蛋白a(LPa) (47±43) mmol/L;利維愛組E2水平(23 ±12) ng/L,TG(1.3±0.7)mmol/L,LPa(28±14) mmol/L.服藥12週後安今益組E2水平(30 ±18) ng/L,TG (1.6±1.1) mmol/L,LPa(37±36) mmol/L;利維愛組E2水平(23 ±9) ng/L,TG(1.1±0.6) mmol/L,LPa(18±12) mmol/L.安今益組服藥後子宮內膜厚度增加,23例服藥中髮生陰道齣血.結論 安今益作為絕經後女性MHT連續聯閤治療新型藥物,能很好緩解絕經後相關癥狀,調節血脂代謝和保護心血管繫統作用彊于利維愛,陰道齣血髮生率高、子宮內膜增厚和乳腺脹痛不適降低瞭使用者依從性.
목적 탐토신형련속연합복방제제안금익(자이순굴라동편)치료녀성절경후증상적림상료효、안전성화대혈지대사영향.방법 채용배대대조회고성림상연구,대2012년1월지2014년10월북경조양의원부과문진취진접수안금익(1 mg 17β-자이순화2 mg굴라동/편,격일1편)치료절경증상녀성27례,화동시기동년령단접수리유애(tibolone 2.5 mg/편,격일1편)치료26례대조,수집림상자료,복약전、복약12주화정약2개월혈청격소、혈지、공복혈당수평,이급분강、유선화경동맥혈관초성수거.결과 량조대상년령、절경시간、체질량지수화림상환병정황구유가비성.복약전안금익조E2수평(12±10) ng/L,감유삼지(TG) (2.0±1.1) mmol/L,지단백a(LPa) (47±43) mmol/L;리유애조E2수평(23 ±12) ng/L,TG(1.3±0.7)mmol/L,LPa(28±14) mmol/L.복약12주후안금익조E2수평(30 ±18) ng/L,TG (1.6±1.1) mmol/L,LPa(37±36) mmol/L;리유애조E2수평(23 ±9) ng/L,TG(1.1±0.6) mmol/L,LPa(18±12) mmol/L.안금익조복약후자궁내막후도증가,23례복약중발생음도출혈.결론 안금익작위절경후녀성MHT련속연합치료신형약물,능흔호완해절경후상관증상,조절혈지대사화보호심혈관계통작용강우리유애,음도출혈발생솔고、자궁내막증후화유선창통불괄강저료사용자의종성.
Objective To compare the clinical and metabolic effects of drospirenone-estradiol (Angeliq) versus tibolone (Livial) in postmenopausal women.Methods Twenty-seven postmenopausal women of group 1 took Angeliq (1 dose every two days) while another group 2 (n =26) received tibolone (2.5 mg every two days) as hormone replacement therapy for 12 weeks.A retrospective analysis was used to evaluate the clinical efficacy,safety and risk factors of cardiovascular metabolism.The clinical data were collected before and after treatment,including personal interview,medical examination and ultrasound imaging of pelvic,breast and carotid artery.Results No statistically significant inter-group differences existed in age or body mass index.Before treatment,the level of E2 was (12 ± 10) ng/L,triglyceride (TG) (2.0 ± 1.1) mmol/L,lipoprotein-a (LPa) (47 ± 43) mmol/L in group 1 versus (23 ± 12) ng/L,(1.3 ± 0.7) mmol/L and (28 ± 14) mmol/L in group 2.After 12-week treatment,(30 ± 18) ng/L,(1.6 ± 1.1) mmol/L and (37 ±36) mmol/L in group 1 versus (23 ±9) ng/L,(1.1 ±0.6) mmol/L and (18 ± 12) mmol/L in group 2.A greater incidence of vaginal bleeding and thicker endometrium were found in group 1.Conclusion Angeliq can relieve menopausal symptoms.And its functions of regulating lipid metabolism and protecting cardiovascular system are better than those of Livial.However,its wider acceptability is limited by vaginal bleeding,thicker endometrium and breast pain.
